Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models

Abstract The impact of first-generation covalent KRASG12C inhibitors has been reduced due to the development of drug resistance, tolerability and challenges combining with immunotherapy. We designed olomorasib, a next-generation GDP-binding KRASG12C inhibitor, for nanomolar potency as well as select...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Shengbin Peng, Youyan Zhang, Xi Lin, Chong Si, Robert Daniel Van Horn, Jack A. Dempsey, Eva Goetz, Robert J. Evans, Andrew Farber, Matthew J. Vandekopple, Wenyu Ming, Hong Gao, Chungping Yu, Wei Guo Xu, Nicholas E. Brown, Michele S. Dowless, Nicholas Pulliam, David A. Barda, Deqi Guo, Serge L. Boulet, Lysian Huber, Andrew Capen, Bonita Jones, Sarah Bogner, Mark A. Castanares, Jennifer Rachelle Stephens, Megan A. Johnson, Carmen L. Curtis, John M. Strelow, Junpeng Xiao, Josh Ballard, Wayne P. Bocchinfuso, Michael J. Chalmers, Jing Wang, Jorg Hendle, Melbert D. Saflor, Danalyn Manglicmot Lagutan, Tarun Gheyi, Anita Sarkar, Margaret Kearins, Frances Tung, Joseph Ho, Logan Rodgers, Jordi Benach, Anton Joseph Frommelt, Lian Zhou, Bradley L. Ackermann, Denis McCann, Anke Klippel, Sean G. Buchanan, James R. Henry, Xueqian Gong
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2026-05-01
סדרה:	Nature Communications
גישה מקוונת:	https://doi.org/10.1038/s41467-026-72650-y
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!